Osavampator

Overview of the drug Osavampator

Osavampator
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Osavampator (development code TAK-653) is a pharmaceutical drug that acts as a positive allosteric modulator of the AMPA receptor. It is being investigated for its potential use in the treatment of major depressive disorder and other neurological disorders.

Mechanism of Action

Osavampator functions as a positive allosteric modulator of the AMPA receptor, which is a subtype of the glutamate receptors in the central nervous system. By enhancing the activity of these receptors, Osavampator may increase synaptic transmission and neuroplasticity, potentially leading to improved cognitive function and mood regulation.

Pharmacology

Osavampator is designed to selectively modulate the AMPA receptors without directly activating them. This selectivity is crucial as it allows for the enhancement of synaptic responses to endogenous glutamate without causing excessive excitotoxicity, which can occur with direct agonists.

Clinical Development

Osavampator is currently in the clinical trial phase, with studies focusing on its efficacy and safety in treating major depressive disorder. The drug is being evaluated for its potential to provide rapid antidepressant effects, similar to those observed with other AMPA receptor modulators.

Potential Applications

Beyond its use in major depressive disorder, Osavampator is being explored for its potential benefits in other conditions such as schizophrenia, bipolar disorder, and cognitive impairment associated with neurodegenerative diseases.

Safety and Tolerability

The safety profile of Osavampator is still under investigation. Early clinical trials suggest that it is generally well-tolerated, with a side effect profile similar to other drugs in its class. Common side effects may include headache, nausea, and dizziness.

Related pages

• AMPA receptor
• Major depressive disorder
• Neuroplasticity
• Glutamate receptor